XML 30 R5.htm IDEA: XBRL DOCUMENT
v3.19.3

Consolidated Statements of Stockholders Equity - USD ($) | Series B Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Deficit [Member] | Noncontrolling Interest [Member] | Total
--- | --- | --- | --- | --- | --- | ---
Balance at Dec. 31, 2017 |  | $ 4,000 | $ 192,670,000 | $ (194,170,000) | $ (1,914,000) | $ (3,410,000)
Balance (in shares) at Dec. 31, 2017 |  | 3,671,014 |  |  |  |
Stock-based compensation | $ 0 | $ 0 | 676,000 | 0 | 0 | 676,000
Fair Value of Warrants issued | 0 | 0 | 9,000 | 0 | 0 | 9,000
Series A Preferred Stock Dividends | 0 | 0 | 0 | (59,000) | 0 | (59,000)
Net loss | $ 0 | 0 | 0 | (2,316,000) | 0 | (2,316,000)
Non-controlling interest |  | 0 | 0 | 0 | (9,000) | (9,000)
Balance at Mar. 31, 2018 |  | $ 4,000 | 193,355,000 | (196,545,000) | (1,923,000) | (5,109,000)
Balance (in shares) at Mar. 31, 2018 |  | 3,671,014 |  |  |  |
Balance at Dec. 31, 2017 |  | $ 4,000 | 192,670,000 | (194,170,000) | (1,914,000) | (3,410,000)
Balance (in shares) at Dec. 31, 2017 |  | 3,671,014 |  |  |  |
Net loss |  |  |  |  |  | (10,194,000)
Non-controlling interest |  |  |  |  |  | (35,000)
Balance at Sep. 30, 2018 |  | $ 5,000 | 200,807,000 | (204,545,000) | (1,948,000) | (5,681,000)
Balance (in shares) at Sep. 30, 2018 |  | 5,349,002 |  |  |  |
Balance at Mar. 31, 2018 |  | $ 4,000 | 193,355,000 | (196,545,000) | (1,923,000) | (5,109,000)
Balance (in shares) at Mar. 31, 2018 |  | 3,671,014 |  |  |  |
Stock-based compensation |  |  | 557,000 |  |  | 557,000
Series A Preferred Stock Dividends |  |  |  | (61,000) |  | (61,000)
Stock issued under "at-the-market" offering |  |  | 400,000 |  |  | 400,000
Stock issued under "at-the-market" offering (in shares) | 0 | 49,490 |  |  |  |
Net loss |  |  |  | (4,198,000) |  | (4,198,000)
Non-controlling interest |  |  |  |  | (16,000) | (16,000)
Balance at Jun. 30, 2018 |  | $ 4,000 | 194,312,000 | (200,804,000) | (1,939,000) | (8,427,000)
Balance (in shares) at Jun. 30, 2018 |  | 3,720,504 |  |  |  |
Stock-based compensation |  |  | 475,000 |  |  | 475,000
Series A Preferred Stock Dividends |  |  |  | (61,000) |  | (61,000)
Stock issued under "at-the-market" offering |  | $ 1,000 | 6,020,000 |  |  | 6,021,000
Stock issued under "at-the-market" offering (in shares) |  | 1,628,498 |  |  |  |
Net loss |  |  |  | (3,680,000) |  | (3,680,000)
Non-controlling interest |  |  |  |  | (9,000) | (9,000)
Balance at Sep. 30, 2018 |  | $ 5,000 | 200,807,000 | (204,545,000) | (1,948,000) | (5,681,000)
Balance (in shares) at Sep. 30, 2018 |  | 5,349,002 |  |  |  |
Balance at Dec. 31, 2018 | $ 5,760,000 | $ 15,000 | 230,754,000 | (219,461,000) | (2,909,000) | 14,159,000
Balance (in shares) at Dec. 31, 2018 | 9,161 | 15,482,083 |  |  |  |
Stock-based compensation | $ 0 | $ 0 | 64,000 | 0 | 0 | 64,000
Series A Preferred Stock Dividends | 0 | 0 | 0 | (61,000) | 0 | (61,000)
Issuance of SYN Biomics Stock | 0 | 0 | (36,000) | 0 | 53,000 | 17,000
Conversion of Series B Preferred Stock to Common | $ (638,000) | $ 1,000 | 1,035,000 | (398,000) | 0 | 0
Conversion of Series B Preferred Stock to Common (in shares) | (1,036) | 900,869 |  |  |  |
Net loss | $ 0 | $ 0 | 0 | (3,512,000) | 0 | (3,512,000)
Non-controlling interest |  | 0 | 0 | 0 | (16,000) | (16,000)
Balance at Mar. 31, 2019 | $ 5,122,000 | $ 16,000 | 231,817,000 | (223,432,000) | (2,872,000) | 10,651,000
Balance (in shares) at Mar. 31, 2019 | 8,125 | 16,382,952 |  |  |  |
Balance at Dec. 31, 2018 | $ 5,760,000 | $ 15,000 | 230,754,000 | (219,461,000) | (2,909,000) | 14,159,000
Balance (in shares) at Dec. 31, 2018 | 9,161 | 15,482,083 |  |  |  |
Net loss |  |  |  |  |  | (12,163,000)
Non-controlling interest |  |  |  |  |  | (73,000)
Balance at Sep. 30, 2019 | $ 4,822,000 | $ 17,000 | 232,485,000 | (232,394,000) | (2,841,000) | 2,089,000
Balance (in shares) at Sep. 30, 2019 | 7,638 | 16,806,430 |  |  |  |
Balance at Mar. 31, 2019 | $ 5,122,000 | $ 16,000 | 231,817,000 | (223,432,000) | (2,872,000) | 10,651,000
Balance (in shares) at Mar. 31, 2019 | 8,125 | 16,382,952 |  |  |  |
Stock-based compensation | $ 0 | $ 0 | 91,000 | 0 | 0 | 91,000
Series A Preferred Stock Dividends | 0 | 0 | 0 | (61,000) | 0 | (61,000)
Issuance of SYN Biomics Stock | 0 | 0 | 0 | 0 | 45,000 | 45,000
Conversion of Series B Preferred Stock to Common | $ (187,000) | $ 1,000 | 303,000 | (117,000) | 0 | 0
Conversion of Series B Preferred Stock to Common (in shares) | (302) | 262,608 |  |  |  |
Net loss |  | $ 0 | 0 | (3,531,000) | 0 | (3,531,000)
Non-controlling interest |  | 0 | 0 | 0 | (27,000) | (27,000)
Balance at Jun. 30, 2019 | $ 4,935,000 | $ 17,000 | 232,211,000 | (227,141,000) | (2,854,000) | 7,168,000
Balance (in shares) at Jun. 30, 2019 | 7,823 | 16,645,560 |  |  |  |
Stock-based compensation | $ 0 | $ 0 | 91,000 | 0 | 0 | 91,000
Series A Preferred Stock Dividends | 0 | 0 | 0 | (63,000) | 0 | (63,000)
Issuance of SYN Biomics Stock | 0 | 0 | 0 | 0 | 43,000 | 43,000
Conversion of Series B Preferred Stock to Common | $ (113,000) | $ 0 | 183,000 | (70,000) | 0 | 0
Conversion of Series B Preferred Stock to Common (in shares) | (185) | 160,870 |  |  |  |
Net loss | $ 0 | $ 0 | 0 | (5,120,000) | 0 | (5,120,000)
Non-controlling interest | 0 | 0 | 0 | 0 | (30,000) | (30,000)
Balance at Sep. 30, 2019 | $ 4,822,000 | $ 17,000 | $ 232,485,000 | $ (232,394,000) | $ (2,841,000) | $ 2,089,000
Balance (in shares) at Sep. 30, 2019 | 7,638 | 16,806,430 |  |  |  |

X
- Definition Represents conversion of preferred stock to common stock + References No definition available. + Details
Name: | syn_ConversionOfSeriesBPreferredStockToCommonStock
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of conversion of series B preferred stock to common stock issued. + References No definition available. + Details
Name: | syn_ConversionOfSeriesBPreferredStockToCommonStockShares
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period at the market offering. + References No definition available. + Details
Name: | syn_StockIssuedDuringPeriodAtMarketOfferingShare
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period at the market offering. + References No definition available. + Details
Name: | syn_StockIssuedDuringPeriodAtMarketOfferingValue
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the value of new stock of syn biomics stock issued. + References No definition available. + Details
Name: | syn_StockIssuedDuringPeriodValueOfSynBiomicsStock
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. + References No definition available. + Details
Name: | us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details
Name: | us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 405 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817 + Details
Name: | us-gaap_DividendsPreferredStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686 + Details
Name: | us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares issued which are neither cancelled nor held in the treasury. + References No definition available. + Details
Name: | us-gaap_SharesOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683 + Details
Name: | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant